Darolutamide: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Darolutamide. Educational only — not medical advice.

Labeled uses

NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: non-metastatic castration-resistant prostate cancer (nmCRPC). (1 ) metastatic castration-sensitive prostate cancer (mCSPC). (1 ) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. (1 )

Source: FDA labeling via NIH DailyMed (set 1a7cb212…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.